Indian Supreme Court stops Glenmark from making generic Januvia

The Supreme Court of India has ordered Glenmark Pharmaceuticals to stop making generic versions of Merck Sharp & Dohme’s diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

China’s medtech shake-up forces rethink on pricing, IP and innovation

3 July 2026 A report warns that procurement reforms in Mainland China, alongside the rise of open robotics platforms, supply chain disruption and GLP-1 drugs, are challenging existing medtech business models.

Asia

‘Blatant imitation’: Indian court blocks copycat pharma branding

22 June 2026 The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.

Asia

Takeda’s China IP head: What pharma is still getting wrong

27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.

More features

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

UPC upholds injunction in Invisalign maker’s software dispute with rival

BioNTech and Pfizer secure big European win over mRNA patent

Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin

Influential Women in IP 2026: Who made the list?

WilmerHale trade secrets expert moves to new firm

UPC revives patent, but timing sinks Guardant’s appeal

Indian Supreme Court stops Glenmark from making generic Januvia

More on this story

Editor's picks

Editor's picks

More features